When analyzing the prognostic value of Ki-67 in LMS, the authors concluded that this marker alone could be used as a survival indicator in LMS patients, although combination of tumor size, mitotic index, and Bcl-2 and CD163 expression worked even better [58]. The gene discussed is BCL2; the disease is neoplasm.